Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors.

Abstract

Simple SummaryAlthough immune checkpoint inhibitors improve the survival of patients with advanced gastrointestinal cancers, they also cause a series of immune-related adverse events, which could sometimes be lethal and may hamper the effectiveness of anticancer therapies. The purpose of this study was to explore clinically accessible biomarkers to predict survival and adverse events in patients with advanced gastrointestinal cancers treated with checkpoint inhibitors. In a retrospective cohort containing 243 patients, we found that early treatment lines, the presence of immune-related adverse events, and a lower posttreatment neutrophil-to-lymphocyte ratio were independent factors predicting superior prognosis. Good physical strength and a low posttreatment neutrophil-to-lymphocyte ratio were independent risk factors for immune-related adverse events. These findings may assist in identifying patients who are more likely to respond to immunotherapy and suffer from fewer toxicities, which is of great value in guiding clinical decisions.Background: Gastrointestinal cancers constitute a major burden of global cancer mortalities. In recent years, the advent of immune checkpoint inhibitors has greatly improved the survival of patients with advanced gastrointestinal cancers, while predictive biomarkers of treatment efficacy and toxicities are still unmet demands. Methods: In our retrospective study, patients with advanced gastrointestinal cancers who received single or double immune checkpoint inhibitors in the Department of Gastrointestinal Oncology in Peking University Cancer Hospital between July 2016 and February 2022 were enrolled. Records of clinicopathological information, survival parameters, safety data, and baseline and posttreatment peripheral blood constituents were retrieved. Cox regression analysis and logistic regression analysis were performed to identify the predictive factors of treatment outcomes and immune-related adverse events. Results: We demonstrated that early treatment lines, the presence of immune-related adverse events, and a lower C2 neutrophil-to-lymphocyte ratio were independent factors predicting a superior objective response rate and progression-free survival in patients treated with immunotherapy. Lower ECOG PS, higher baseline albumin, and lower C2 neutrophil-to-lymphocyte ratios were independent risk factors for the onset of immune-related adverse events. Patients who succumbed to immune-related adverse events during immunotherapy presented better survival. Conclusion: Our results indicate that peripheral blood markers have potential for predicting treatment outcomes and immune-related adverse events in patients with advanced gastrointestinal cancer. Prospective validations are warranted.